These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15850918)

  • 21. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer.
    Sherertz T; Wallner K; Merrick G; Ford E; Sutlief S; Cavanagh W; Butler W; True L
    Brachytherapy; 2004; 3(3):130-5. PubMed ID: 15533804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
    Merrick GS; Butler WM; Dorsey AT; Lief JH
    Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK; Adams MT; Motta J
    Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical correlates of high intraprostatic brachytherapy dose volumes.
    Jones S; Wallner K; Merrick G; Corriveau J; Sutlief S; True L; Butler W
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):328-33. PubMed ID: 12023136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer.
    Merrick GS; Wallner KE; Butler WM; Galbreath RW; Allen ZA; Adamovich E; True L
    BJU Int; 2006 Aug; 98(2):324-8. PubMed ID: 16879672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosimetry of an extracapsular anulus following permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Allen ZA; Kurko B; Anderson RL; Grammer R; Galbreath RW; True L; Adamovich E
    Am J Clin Oncol; 2007 Jun; 30(3):228-33. PubMed ID: 17551297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate brachytherapy post-implant dosimetry: a comparison between higher and lower source density.
    Thomas CW; Kruk A; McGahan CE; Spadinger I; Morris WJ
    Radiother Oncol; 2007 Apr; 83(1):18-24. PubMed ID: 17368844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
    Robert Lee W; Deguzman AF; McMullen KP; McCullough DL
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):52-9. PubMed ID: 15629593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
    J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric quality endpoints for low-dose-rate prostate brachytherapy using biological effective dose (BED) vs. conventional dose.
    Singh R; Al-Hallaq H; Pelizzari CA; Zagaja GP; Chen A; Jani AB
    Med Dosim; 2003; 28(4):255-9. PubMed ID: 14684190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.